Phaseline

Targets › FABP

FABP: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2028.

Open in Phaseline: the race on FABP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Centre Hospitalier Universitaire de BesanconMP0317
FAP-dependent CD40 agonist
FABPPhase 2Advanced Biliary Tract CarcinomaNov 2028

Conditions

Advanced Biliary Tract Carcinoma (1)

Modalities

antibody (1)

Companies

Centre Hospitalier Universitaire de Besancon (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.